DOCT.L vs. SBIO.L

Last updated Jun 5, 2026

DOCT.L (L&G Healthcare Breakthrough UCITS ETF) and SBIO.L (Invesco Nasdaq Biotech UCITS ETF) are both Health & Biotech Equities funds - DOCT.L tracks the MSCI World/Health Care NR USD while SBIO.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past 5 years, DOCT.L returned -3.81%/yr vs 4.66%/yr for SBIO.L. A 0.79 correlation means they provide meaningful diversification when combined. DOCT.L charges 0.49%/yr vs 0.40%/yr for SBIO.L.

Performance

DOCT.L vs. SBIO.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in L&G Healthcare Breakthrough UCITS ETF (DOCT.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DOCT.L achieves a 0.41% return, which is significantly lower than SBIO.L's 4.34% return.

DOCT.L

• 1D: 5.27%
• 1M: 6.77%
• YTD: 0.41%
• 6M: 0.07%
• 1Y: 31.20%
• 3Y*: 7.08%
• 5Y*: -3.81%
• 10Y*: —

SBIO.L

• 1D: 3.10%
• 1M: 0.91%
• YTD: 4.34%
• 6M: 2.82%
• 1Y: 41.33%
• 3Y*: 12.99%
• 5Y*: 4.66%
• 10Y*: 7.49%

*Multi-year figures are annualized to reflect compound growth (CAGR)

DOCT.L vs. SBIO.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
DOCT.L L&G Healthcare Breakthrough UCITS ETF	0.41%	24.88%	1.98%	-1.20%	-33.86%	0.19%	66.94%	5.40%
SBIO.L Invesco Nasdaq Biotech UCITS ETF	4.34%	32.89%	-2.00%	6.14%	-11.85%	-0.49%	27.35%	9.91%

Correlation

The correlation between DOCT.L and SBIO.L is 0.73, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.73
Correlation (3Y) Calculated over the trailing 3-year period	0.74
Correlation (5Y) Calculated over the trailing 5-year period	0.78
Correlation (All Time) Calculated using the full available price history since Jul 3, 2019	0.79

The correlation between DOCT.L and SBIO.L has been stable across timeframes, ranging from 0.73 to 0.79 - a consistent structural relationship.

DOCT.L vs. SBIO.L - Sectors Allocation Comparison

Sectors	DOCT.L	SBIO.L
Healthcare	98.3%	100.0%
Technology	1.7%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Utilities	-	-

Return for Risk

DOCT.L vs. SBIO.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DOCT.L

DOCT.L Risk / Return Rank: 40
DOCT.L Sharpe Ratio Rank: 43
DOCT.L Sortino Ratio Rank: 46
DOCT.L Omega Ratio Rank: 41
DOCT.L Calmar Ratio Rank: 38
DOCT.L Martin Ratio Rank: 31

SBIO.L

SBIO.L Risk / Return Rank: 72
SBIO.L Sharpe Ratio Rank: 64
SBIO.L Sortino Ratio Rank: 66
SBIO.L Omega Ratio Rank: 57
SBIO.L Calmar Ratio Rank: 89
SBIO.L Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DOCT.L vs. SBIO.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Healthcare Breakthrough UCITS ETF (DOCT.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DOCT.L	SBIO.L	Difference
Sharpe ratio: Return per unit of total volatility	1.48	2.09	-0.61
Sortino ratio: Return per unit of downside risk	2.25	3.01	-0.76
Omega ratio: Gain probability vs. loss probability	1.26	1.35	-0.08
Calmar ratio: Return relative to maximum drawdown	1.82	5.38	-3.56
Martin ratio: Return relative to average drawdown	4.42	16.56	-12.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DOCT.L vs. SBIO.L - Sharpe Ratio Comparison

The current DOCT.L Sharpe Ratio is 1.48, which is comparable to the SBIO.L Sharpe Ratio of 2.09. The chart below compares the historical Sharpe Ratios of DOCT.L and SBIO.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	DOCT.L	SBIO.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.48	2.09	-0.61
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.16	0.22	-0.38
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.34	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	0.27	-0.04

Drawdowns

DOCT.L vs. SBIO.L - Drawdown Comparison

The maximum DOCT.L drawdown since its inception was -57.55%, which is greater than SBIO.L's maximum drawdown of -39.44%. Use the drawdown chart below to compare losses from any high point for DOCT.L and SBIO.L.

Drawdown Indicators

	DOCT.L	SBIO.L	Difference
Max Drawdown Largest peak-to-trough decline	-57.55%	-39.44%	-18.11%
Max Drawdown (1Y) Largest decline over 1 year	-17.02%	-7.64%	-9.38%
Max Drawdown (3Y) Largest decline over 3 years	-28.80%	-26.88%	-1.92%
Max Drawdown (5Y) Largest decline over 5 years	-55.82%	-38.33%	-17.49%
Max Drawdown (10Y) Largest decline over 10 years	—	-38.33%	—
Current Drawdown Current decline from peak	-29.74%	-2.84%	-26.90%
Average Drawdown Average peak-to-trough decline	-29.05%	-16.83%	-12.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.04%	2.49%	+4.55%

Volatility

DOCT.L vs. SBIO.L - Volatility Comparison

L&G Healthcare Breakthrough UCITS ETF (DOCT.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L) have volatilities of 6.75% and 6.55%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DOCT.L	SBIO.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.75%	6.55%	+0.20%
Volatility (6M) Calculated over the trailing 6-month period	15.76%	15.27%	+0.49%
Volatility (1Y) Calculated over the trailing 1-year period	21.03%	19.67%	+1.36%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.01%	21.21%	+2.80%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	24.76%	22.23%	+2.53%

DOCT.L vs. SBIO.L - Expense Ratio Comparison

DOCT.L has a 0.49% expense ratio, which is higher than SBIO.L's 0.40% expense ratio.

Dividends

DOCT.L vs. SBIO.L - Dividend Comparison

Neither DOCT.L nor SBIO.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both DOCT.L and SBIO.L in my portfolio?

DOCT.L and SBIO.L have a correlation of 0.73, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, DOCT.L or SBIO.L?

On fees, SBIO.L is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, DOCT.L or SBIO.L?

SBIO.L is cheaper with a 0.40% expense ratio, compared with 0.49% for DOCT.L.

What is the main difference between DOCT.L and SBIO.L?

DOCT.L tracks MSCI World/Health Care NR USD, while SBIO.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: Legal & General and Invesco. Their fees differ too: 0.49% for DOCT.L and 0.40% for SBIO.L.